pharmaceuticals

pharmaceuticals Articles

Trevena charged after the FDA granted a Breakthrough Therapy designation to its lead product candidate for the management of acute pain.
Allergan reported better-than-expected fourth-quarter financial results before the markets opened on Monday.
Over the past week, Zafgen and a few other biotech companies made impressive runs. These moves were the result of positive trial results and an FDA meeting.
AstraZeneca has announced that the European Commission granted marketing authorization for two of its treatments: Zurampic for gout and Brilique for heart attack patients.
Aerie Pharmaceuticals was one of the more bullish health care stocks on Thursday morning, following the release of its interim safety results.
Regulus Therapeutics has reported positive interim results from its Phase 2 study for the treatment of hepatitis C virus (HCV) infection.
Ocular Therapeutix led the bulls in early trading indications on Thursday, following a positive meeting with the FDA.
In 2016 alone, this stock has taken a beating, and unless this company can turn itself around in the near future, it could be the end.
Spring Bank Pharmaceuticals has amended it filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
This clinical-stage biopharmaceutical company focused on complex biosimilar therapeutics has filed for an IPO.
Baxalta is scheduled to report fourth-quarter and full-year results before markets open on Tuesday.
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
These biotech companies 24/7 Wall St. has picked stood out from the rest with big moves over the course of last week.
Hutchinson China MediTech has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Syndax Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).